Renaissance Technologies LLC Acquires Shares of 239,800 Adaptive Biotechnologies Corporation $ADPT

Posted by Francis Steltz on Aug 9th, 2026

Renaissance Technologies LLC acquired a new stake in Adaptive Biotechnologies Corporation (NASDAQ:ADPT – Free Report) during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 239,800 shares of the company’s stock, valued at approximately $3,328,000. Renaissance Technologies LLC owned about 0.15% of Adaptive Biotechnologies at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Ameriprise Financial Inc. lifted its position in Adaptive Biotechnologies by 84.3% during the third quarter. Ameriprise Financial Inc. now owns 5,971,706 shares of the company’s stock valued at $89,337,000 after purchasing an additional 2,731,648 shares during the period. Price T Rowe Associates Inc. MD grew its position in Adaptive Biotechnologies by 303.4% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 4,387,361 shares of the company’s stock worth $71,252,000 after purchasing an additional 3,299,635 shares during the period. Westfield Capital Management Co. LP purchased a new position in shares of Adaptive Biotechnologies during the 4th quarter valued at about $65,942,000. Geode Capital Management LLC raised its stake in shares of Adaptive Biotechnologies by 3.3% during the 4th quarter. Geode Capital Management LLC now owns 3,511,855 shares of the company’s stock valued at $57,041,000 after buying an additional 110,825 shares during the last quarter. Finally, State Street Corp lifted its holdings in shares of Adaptive Biotechnologies by 3.3% in the 4th quarter. State Street Corp now owns 3,181,644 shares of the company’s stock valued at $51,670,000 after buying an additional 102,362 shares during the period. Institutional investors and hedge funds own 99.17% of the company’s stock.

Adaptive Biotechnologies Stock Performance

NASDAQ:ADPT opened at $24.93 on Friday. The company has a current ratio of 4.79, a quick ratio of 4.68 and a debt-to-equity ratio of 2.22. The company’s 50-day moving average price is $20.40 and its 200-day moving average price is $16.88. Adaptive Biotechnologies Corporation has a twelve month low of $11.85 and a twelve month high of $24.96. The company has a market cap of $3.98 billion, a P/E ratio of -60.80 and a beta of 2.08.

Adaptive Biotechnologies (NASDAQ:ADPT – Get Free Report) last posted its quarterly earnings results on Wednesday, July 29th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.12). Adaptive Biotechnologies had a negative net margin of 20.73% and a negative return on equity of 36.81%. The company had revenue of $71.55 million during the quarter, compared to analysts’ expectations of $65.44 million. During the same quarter last year, the company earned ($0.17) earnings per share. Adaptive Biotechnologies’s revenue for the quarter was up 21.5% on a year-over-year basis. On average, sell-side analysts forecast that Adaptive Biotechnologies Corporation will post -0.4 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on ADPT. Guggenheim upped their target price on Adaptive Biotechnologies from $22.00 to $25.00 and gave the stock a “buy” rating in a research note on Thursday, July 30th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research report on Friday, July 17th. Piper Sandler boosted their price target on Adaptive Biotechnologies from $20.00 to $27.50 and gave the company an “overweight” rating in a report on Tuesday. JPMorgan Chase & Co. lowered their price objective on Adaptive Biotechnologies from $21.00 to $19.00 and set an “overweight” rating on the stock in a research report on Wednesday, May 6th. Finally, Morgan Stanley raised their price objective on shares of Adaptive Biotechnologies from $20.00 to $22.00 and gave the stock an “equal weight” rating in a research note on Thursday, July 30th. Five equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $24.42.

Check Out Our Latest Research Report on ADPT

Insider Buying and Selling

In other news, insider Francis Lo sold 44,838 shares of the business’s stock in a transaction dated Thursday, July 2nd. The shares were sold at an average price of $22.59, for a total transaction of $1,012,890.42. Following the transaction, the insider owned 230,713 shares of the company’s stock, valued at approximately $5,211,806.67. The trade was a 16.27% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Harlan S. Robins sold 492,400 shares of the business’s stock in a transaction dated Tuesday, July 21st. The shares were sold at an average price of $21.89, for a total transaction of $10,778,636.00. Following the transaction, the insider directly owned 812,058 shares in the company, valued at approximately $17,775,949.62. The trade was a 37.75% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 1,307,086 shares of company stock valued at $27,859,739 in the last quarter. Corporate insiders own 5.70% of the company’s stock.

Adaptive Biotechnologies Profile

(Free Report)

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.